Cognitive · Investigational
Orexin A
No lawful US pathway
01 · Overview
Orexin A (hypocretin-1) is a 33-amino acid neuropeptide produced by neurons in the lateral and posterior hypothalamus, first identified as a regulator of feeding (PMID 9491897). It activates both orexin receptor 1 (OX1R) and orexin receptor 2 (OX2R) and plays a central role in sustaining wakefulness.
Most people with narcolepsy with cataplexy have low or undetectable orexin levels due to loss of orexin-producing neurons, making orexin replacement a rational therapeutic strategy (PMID 15070772).
02 · Research summary & key findings
In orexin neuron-ablated mice, central administration of orexin A acutely suppressed cataplexy and increased wakefulness for about 3 hours (PMID 15070772). Small placebo-controlled crossover studies of intranasal orexin A in people with narcolepsy with cataplexy found reduced REM sleep and fewer wake-to-REM transitions, and fewer attention errors, but no significant increase in wakefulness (PMID 22036605, PMID 24406723). A systematic review concluded that orexin did not relieve daytime sleepiness in these human studies (PMID 39898129). Therapeutic development has since focused on orexin receptor agonists rather than the native peptide; a small-molecule OX2R agonist suppressed cataplexy in mouse models (PMID 28507129).
03 · Regulatory status
Orexin A is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
No lawful pathway today
Orexin A is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding. If you are working on the goal it is studied for, a licensed clinician can tell you what is lawfully available, which may be something else.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Looking for a lawful, clinician-prescribed option for cognitive support?
Orexin A is an investigational compound, is not FDA-approved, and has no lawful US compounding pathway, so we do not offer it and no clinician we work with will prescribe it. Products sold online as “research chemicals” are not made or tested to the standards required of medicines. If you are working on cognitive support, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Intracerebroventricular
References
- [1]Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice Proc Natl Acad Sci U S A, 2004. PMID 15070772
- [2]Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy Sleep Med, 2011. PMID 22036605
- [3]The effect of intranasal orexin-A (hypocretin-1) on sleep, wakefulness and attention in narcolepsy with cataplexy Behav Brain Res, 2014. PMID 24406723
- [4]Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models Proc Natl Acad Sci U S A, 2017. PMID 28507129
- [5]Treatment of Narcolepsy Type 1 With Orexin: A Systematic Review Cureus, 2024. PMID 39898129
- [6]Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior Cell, 1998. PMID 9491897
Primary literature
- PubMed: "Orexin A"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Orexin A"
Registered interventional and observational studies, including status and phase.
- PubChem: "Orexin A"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Cognitive
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.